ScandiDos AB (publ) (SDOS.ST)
SEK 1.64
(-1.2%)
SEK 1.64
(-1.2%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 37.18 Million SEK | 20.86% |
| 2022 | 30.76 Million SEK | 6.14% |
| 2021 | 28.98 Million SEK | -9.36% |
| 2020 | 31.98 Million SEK | 29.27% |
| 2019 | 24.74 Million SEK | -39.02% |
| 2018 | 40.56 Million SEK | 107.55% |
| 2017 | 19.54 Million SEK | 0.33% |
| 2016 | 19.48 Million SEK | -23.57% |
| 2015 | 25.49 Million SEK | 40.94% |
| 2014 | 18.08 Million SEK | 35.93% |
| 2013 | 13.3 Million SEK | -30.67% |
| 2012 | 19.19 Million SEK | 58.75% |
| 2011 | 12.08 Million SEK | 62.99% |
| 2010 | 7.41 Million SEK | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 34.33 Million SEK | -7.68% |
| 2023 Q3 | 33.88 Million SEK | -7.75% |
| 2023 FY | 37.18 Million SEK | 20.86% |
| 2023 Q1 | 36.04 Million SEK | 17.14% |
| 2023 Q4 | 37.18 Million SEK | 9.73% |
| 2023 Q2 | 36.73 Million SEK | 1.92% |
| 2022 Q1 | 34.66 Million SEK | 19.6% |
| 2022 Q2 | 30.46 Million SEK | -12.13% |
| 2022 FY | 30.76 Million SEK | 6.14% |
| 2022 Q3 | 29.6 Million SEK | -2.82% |
| 2022 Q4 | 30.76 Million SEK | 3.94% |
| 2021 Q3 | 28.89 Million SEK | 1.75% |
| 2021 Q4 | 28.98 Million SEK | 0.34% |
| 2021 FY | 28.98 Million SEK | -9.36% |
| 2021 Q1 | 28.75 Million SEK | -10.1% |
| 2021 Q2 | 28.39 Million SEK | -1.25% |
| 2020 Q2 | 28.95 Million SEK | 1.73% |
| 2020 FY | 31.98 Million SEK | 29.27% |
| 2020 Q1 | 28.46 Million SEK | 15.03% |
| 2020 Q4 | 31.98 Million SEK | 12.11% |
| 2020 Q3 | 28.52 Million SEK | -1.46% |
| 2019 Q3 | 24.51 Million SEK | 6.18% |
| 2019 FY | 24.74 Million SEK | -39.02% |
| 2019 Q4 | 24.74 Million SEK | 0.91% |
| 2019 Q2 | 23.09 Million SEK | -13.09% |
| 2019 Q1 | 26.56 Million SEK | -34.51% |
| 2018 Q1 | 21.25 Million SEK | 8.76% |
| 2018 FY | 40.56 Million SEK | 107.55% |
| 2018 Q4 | 40.56 Million SEK | 26.83% |
| 2018 Q3 | 31.98 Million SEK | 24.22% |
| 2018 Q2 | 25.75 Million SEK | 21.13% |
| 2017 Q1 | 19.1 Million SEK | -1.94% |
| 2017 Q4 | 19.54 Million SEK | 0.49% |
| 2017 Q3 | 19.45 Million SEK | 9.63% |
| 2017 Q2 | 17.74 Million SEK | -7.13% |
| 2017 FY | 19.54 Million SEK | 0.33% |
| 2016 Q4 | 19.48 Million SEK | 1.51% |
| 2016 Q2 | 19.05 Million SEK | -23.88% |
| 2016 Q3 | 19.19 Million SEK | 0.71% |
| 2016 Q1 | 25.03 Million SEK | -1.79% |
| 2016 FY | 19.48 Million SEK | -23.57% |
| 2015 Q2 | 15.43 Million SEK | 2.5% |
| 2015 Q4 | 25.49 Million SEK | 40.41% |
| 2015 Q3 | 18.15 Million SEK | 17.61% |
| 2015 FY | 25.49 Million SEK | 40.94% |
| 2015 Q1 | 15.06 Million SEK | -16.73% |
| 2014 FY | 18.08 Million SEK | 35.93% |
| 2014 Q3 | 13.7 Million SEK | 25.24% |
| 2014 Q2 | 10.94 Million SEK | -1.32% |
| 2014 Q1 | 11.09 Million SEK | -16.65% |
| 2014 Q4 | 18.08 Million SEK | 31.96% |
| 2013 Q4 | 13.3 Million SEK | -22.84% |
| 2013 FY | 13.3 Million SEK | -30.67% |
| 2013 Q1 | - SEK | -100.0% |
| 2013 Q3 | 17.24 Million SEK | 0.0% |
| 2012 Q4 | 19.19 Million SEK | 0.0% |
| 2012 FY | 19.19 Million SEK | 58.75% |
| 2011 FY | 12.08 Million SEK | 62.99% |
| 2010 FY | 7.41 Million SEK | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Acarix AB (publ) | 10.99 Million SEK | -238.116% |
| ADDvise Group AB (publ) | 2.67 Billion SEK | 98.609% |
| ADDvise Group AB (publ) | 2.67 Billion SEK | 98.609% |
| Arcoma AB | 33.3 Million SEK | -11.653% |
| Bactiguard Holding AB (publ) | 329.7 Million SEK | 88.721% |
| BICO Group AB (publ) | 3.26 Billion SEK | 98.861% |
| Boule Diagnostics AB (publ) | 279.9 Million SEK | 86.715% |
| CellaVision AB (publ) | 212.32 Million SEK | 82.486% |
| Clinical Laserthermia Systems AB (publ) | 14.19 Million SEK | -161.929% |
| Chordate Medical Holding AB (publ) | 6.86 Million SEK | -441.365% |
| C-Rad AB (publ) | 122.4 Million SEK | 69.619% |
| Duearity AB (publ) | 17.53 Million SEK | -112.128% |
| Dignitana AB (publ) | 37.56 Million SEK | 1.014% |
| Episurf Medical AB (publ) | 19.8 Million SEK | -87.808% |
| Getinge AB (publ) | 24.69 Billion SEK | 99.849% |
| Scandinavian Real Heart AB (Publ) | 20.6 Million SEK | -80.512% |
| Iconovo AB (publ) | 14.55 Million SEK | -155.506% |
| Integrum AB (publ) | 22.07 Million SEK | -68.469% |
| Luxbright AB (publ) | 7 Million SEK | -431.219% |
| Mentice AB (publ) | 163.55 Million SEK | 77.264% |
| OssDsign AB (publ) | 105.25 Million SEK | 64.671% |
| Paxman AB (publ) | 44.5 Million SEK | 16.453% |
| Promimic AB (publ) | 16.15 Million SEK | -130.168% |
| Qlife Holding AB (publ) | 62.16 Million SEK | 40.186% |
| SciBase Holding AB (publ) | 21.27 Million SEK | -74.763% |
| Sectra AB (publ) | 1.64 Billion SEK | 97.734% |
| Sedana Medical AB (publ) | 44.06 Million SEK | 15.605% |
| Senzime AB (publ) | 58.06 Million SEK | 35.958% |
| SpectraCure AB (publ) | 14.97 Million SEK | -148.321% |
| Stille AB | 172.64 Million SEK | 78.46% |
| Vitrolife AB (publ) | 3.66 Billion SEK | 98.986% |
| Xvivo Perfusion AB (publ) | 250.56 Million SEK | 85.159% |